Pfizer’s investigational candidate combo cuts prostate cancer progression by 49% in phase 1
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, when combined with Xtandi, reduced prostate cancer progression by 49% compared with Xtandi alone.
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, when combined with Xtandi, reduced prostate cancer progression by 49% compared with Xtandi alone.
